HUP0304039A2 - Eljárás CETP-inhibitorok előállítására - Google Patents

Eljárás CETP-inhibitorok előállítására

Info

Publication number
HUP0304039A2
HUP0304039A2 HU0304039A HUP0304039A HUP0304039A2 HU P0304039 A2 HUP0304039 A2 HU P0304039A2 HU 0304039 A HU0304039 A HU 0304039A HU P0304039 A HUP0304039 A HU P0304039A HU P0304039 A2 HUP0304039 A2 HU P0304039A2
Authority
HU
Hungary
Prior art keywords
methods
cetp inhibitors
production
preparing
preparing cetp
Prior art date
Application number
HU0304039A
Other languages
English (en)
Inventor
David Burns Damon
Robert Wayne Dugger
Robert William Scott
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0304039A2 publication Critical patent/HUP0304039A2/hu
Publication of HUP0304039A3 publication Critical patent/HUP0304039A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

A találmány az (IA) és (IB) képletű koleszteril-észter transzferprotein (CETP) inhibitorok előállítására és az előállításábanalkalmazott a (VIIIA) képletű és a (VIIIB) általános képletűköztitermékre, utóbbi képletben R1 jelentése adott esetbenhelyettesített benzilcsoport, valamint ezek előállítására vonatkozik. Ó
HU0304039A 2001-04-30 2002-04-08 Methods for preparing cetp inhibitors HUP0304039A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28752201P 2001-04-30 2001-04-30
PCT/IB2002/001214 WO2002088085A2 (en) 2001-04-30 2002-04-08 Methods and intermediates for preparing 4-aminoquinoline cetp inhibitors

Publications (2)

Publication Number Publication Date
HUP0304039A2 true HUP0304039A2 (hu) 2004-03-29
HUP0304039A3 HUP0304039A3 (en) 2005-10-28

Family

ID=23103272

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0304039A HUP0304039A3 (en) 2001-04-30 2002-04-08 Methods for preparing cetp inhibitors
HU0304041A HU225777B1 (en) 2001-04-30 2002-04-08 Compounds useful as intermediates for 4-aminoquinoline derivatwes and process for producing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU0304041A HU225777B1 (en) 2001-04-30 2002-04-08 Compounds useful as intermediates for 4-aminoquinoline derivatwes and process for producing them

Country Status (25)

Country Link
US (3) US6689897B2 (hu)
EP (2) EP1383734B1 (hu)
JP (2) JP3924250B2 (hu)
KR (2) KR100639745B1 (hu)
CN (3) CN100357265C (hu)
AR (3) AR036331A1 (hu)
AT (2) ATE321755T1 (hu)
AU (1) AU2002253448B2 (hu)
BR (2) BR0209291A (hu)
CA (2) CA2445623A1 (hu)
CZ (2) CZ20032898A3 (hu)
DE (2) DE60210265T2 (hu)
DK (2) DK1383734T3 (hu)
ES (2) ES2256461T3 (hu)
HK (1) HK1062294A1 (hu)
HU (2) HUP0304039A3 (hu)
IL (2) IL157544A0 (hu)
MX (2) MXPA03009935A (hu)
PL (2) PL366700A1 (hu)
PT (1) PT1425270E (hu)
RU (2) RU2265010C2 (hu)
TW (1) TWI250974B (hu)
WO (2) WO2002088069A2 (hu)
YU (2) YU84303A (hu)
ZA (2) ZA200306600B (hu)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
JP2006021999A (ja) * 2002-07-12 2006-01-26 Kaneka Corp 光学活性β−アミノニトリル化合物およびその対掌体アミド化合物の製造方法
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
AU2003277285B2 (en) 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
ATE461700T1 (de) 2002-12-20 2010-04-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
WO2004074255A2 (en) * 2003-02-18 2004-09-02 Takasago International Corporation Method for producing an optically active tetrahydroquinoline
US7223859B2 (en) 2003-03-17 2007-05-29 Pfizer Inc. Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative
EP1604975A4 (en) * 2003-03-17 2006-11-02 Kaneka Corp PROCESSES FOR PRODUCING (R) -3- 4- (TRIFLUOROMETHYL) -PHENYLAMINO-PENTANAMIDE DERIVATIVES
MXPA06003357A (es) 2003-09-26 2006-06-08 Japan Tobacco Inc Metodo para inhibir la produccion de lipoproteina remanente.
JP4773969B2 (ja) * 2003-10-08 2011-09-14 イーライ リリー アンド カンパニー 脂質代謝異常の治療ための化合物及び方法
DE602004020649D1 (de) * 2003-11-07 2009-05-28 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
CN101018770A (zh) * 2004-04-07 2007-08-15 千禧药品公司 炎性疾病治疗用pgd2受体拮抗剂
MXPA06014716A (es) * 2004-06-24 2007-03-12 Lilly Co Eli Compuestos y metodos para el tratamiento de dislipidemia.
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
UA90706C2 (ru) 2005-02-24 2010-05-25 Милленниум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
KR20080016933A (ko) * 2005-06-20 2008-02-22 아스트라제네카 아베 (알콕시카보닐아미노)알킬 설포네이트의 제조 방법
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
DE102006031149A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006032391A1 (de) * 2006-07-04 2008-01-17 Merck Patent Gmbh Fluortenside
DE102006031151A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031143A1 (de) * 2006-07-04 2008-01-24 Merck Patent Gmbh Fluortenside
DE102006031262A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
US9371294B2 (en) 2011-04-12 2016-06-21 Chong Kun Dang Pharmaceutical Corp. Cycloalkenyl aryl derivatives for CETP inhibitor
BR112014000333A2 (pt) 2011-07-08 2017-02-07 Novartis Ag método de tratamento de aterosclerose em sujeitos com triglicerídeo alto
NZ708079A (en) 2013-01-31 2016-07-29 Chong Kun Dang Pharm Corp Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
EP3039740B1 (en) * 2013-11-11 2016-11-09 Lonza Ltd Method for preparation of cyano compounds of the 13th group with a lewis acid
EP4083022A1 (en) * 2014-08-12 2022-11-02 NewAmsterdam Pharma B.V. Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
CN105294559B (zh) * 2015-06-24 2017-11-14 厦门法茉维特动物药业有限公司 一种医药中间体4‑氨基喹啉类化合物的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1097158B1 (en) 1998-07-10 2006-01-25 Massachusetts Institute Of Technology Ligands for metals and metal-catalyzed processes
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
AR036331A1 (es) 2004-09-01
BR0209238A (pt) 2004-06-15
WO2002088069A3 (en) 2003-02-20
ES2259080T3 (es) 2006-09-16
RU2259355C2 (ru) 2005-08-27
EP1383734B1 (en) 2006-02-01
HUP0304041A3 (en) 2005-08-29
US20020177716A1 (en) 2002-11-28
AR035963A1 (es) 2004-07-28
WO2002088069A9 (en) 2003-12-04
HUP0304041A2 (hu) 2004-04-28
HK1062294A1 (en) 2004-10-29
MXPA03009936A (es) 2004-01-29
WO2002088085A3 (en) 2004-03-25
JP3924251B2 (ja) 2007-06-06
US6706881B2 (en) 2004-03-16
TWI250974B (en) 2006-03-11
CZ20032900A3 (cs) 2004-06-16
ZA200306600B (en) 2004-08-25
RU2003131870A (ru) 2005-01-27
CA2445693A1 (en) 2002-11-07
JP2004531541A (ja) 2004-10-14
CZ20032898A3 (cs) 2004-07-14
CN1680292A (zh) 2005-10-12
IL157544A0 (en) 2004-03-28
RU2265010C2 (ru) 2005-11-27
AR044706A2 (es) 2005-09-21
PT1425270E (pt) 2006-07-31
CN1267411C (zh) 2006-08-02
DE60209004D1 (de) 2006-04-13
KR20040030603A (ko) 2004-04-09
KR100639745B1 (ko) 2006-10-30
US20030073843A1 (en) 2003-04-17
DE60209004T2 (de) 2006-09-28
CN100357265C (zh) 2007-12-26
EP1383734A2 (en) 2004-01-28
US6689897B2 (en) 2004-02-10
YU84403A (sh) 2006-08-17
KR20040015200A (ko) 2004-02-18
ZA200306599B (en) 2004-10-22
YU84303A (sh) 2006-05-25
IL157546A0 (en) 2004-03-28
AU2002253448B2 (en) 2007-07-05
JP3924250B2 (ja) 2007-06-06
EP1425270A2 (en) 2004-06-09
WO2002088069A2 (en) 2002-11-07
EP1425270B1 (en) 2006-03-29
HUP0304039A3 (en) 2005-10-28
HU225777B1 (en) 2007-08-28
DK1383734T3 (da) 2006-05-15
ATE321755T1 (de) 2006-04-15
JP2004527556A (ja) 2004-09-09
KR100591998B1 (ko) 2006-06-22
PL366700A1 (en) 2005-02-07
ATE316957T1 (de) 2006-02-15
MXPA03009935A (es) 2004-01-29
RU2003131871A (ru) 2005-04-10
DE60210265T2 (de) 2006-10-12
CN1505609A (zh) 2004-06-16
US20030216576A1 (en) 2003-11-20
WO2002088085A2 (en) 2002-11-07
ES2256461T3 (es) 2006-07-16
CN1297541C (zh) 2007-01-31
DK1425270T3 (da) 2006-07-03
PL366584A1 (en) 2005-02-07
US6600045B2 (en) 2003-07-29
BR0209291A (pt) 2004-07-13
CA2445623A1 (en) 2002-11-07
DE60210265D1 (de) 2006-05-18
CN1529696A (zh) 2004-09-15

Similar Documents

Publication Publication Date Title
HUP0304039A2 (hu) Eljárás CETP-inhibitorok előállítására
BR0307432A (pt) Difluormetiltiazolilcarboxanilidas
DK1543002T3 (da) Fremstilling af 1H-imidazo (4,5-c) quinolin-4-aminer via 1H-imidazo (4,5-c) quinolin-4-phtalimid mellemprodukter
HUP0401647A2 (hu) Új béta-fenil-alfa-oxi-propionsav-származékok, előállítási eljárásaik és gyógyszerészetileg fontos vegyületek előállításánál történő felhasználásuk
HK1089444A1 (en) Dihydropteridinones, method for the production and use thereof in the form of drugs
NO20025590D0 (no) Fenylglycin-derivater
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
AU2002319814A1 (en) Substituted 1h-dihydropyrazoles, their preparation and use
TR200401962T4 (tr) Heteroaromatik karboksamid türevleri ve bunların IKK-2 enziminin inhibitörleri olarak kullanımı
ECSP034460A (es) Nuevos compuestos heterociclicos, su preparacion y su utilizacion como medicamentos, en especial como antibacterianos
AU2482800A (en) Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
HUP0300701A2 (hu) Zolpidem hemitartarát, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
BR0305767A (pt) Métodos e composições para a preparação de derivados de ácido 4-substituìdo 3-hidroxibutìrico
BR0015836A (pt) Cristal de 4-carboxiamino-2-etil-1,2,3,4-tetra-hidroquinolina como inibidor de cetp
HUP0204010A2 (hu) Új szertralin-hidroklorid polimorfok, eljárás az előállításukra, az új polimorfokat tartalmazó gyógyszerkészítmények és alkalmazásuk
BRPI0410861A (pt) métodos e composições para a produção de aminoácidos
HUP0103089A2 (hu) Beraproszt észter előállítása szelektív oxidációval
AU2003230831A1 (en) ANHYDROUS CRYSTALLINE FORMS I AND II OF 1-CYCLOPROPYL-6-FLUORO-8-METHOXY-7-(3-METHYL-1-PIPERAZINYL) 4-OXO-l, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID (GATIFLOXACIN)
BR0309526A (pt) Metiltiofenocarboxanilidas
FR2854402B1 (fr) Nouveau procede et intermediaires de preparation de composes 19-nor-steroides
NO20053829L (no) Fremgangsmate og intermediater for fremstilling av olanzapin.
HUP0202383A2 (hu) Eljárás 2-(2-aril-morfolin-il)-etanol-származékok előállítása és közbenső termékek
EA200300771A1 (ru) Новая соль бензоилгуанидина
MXPA03010613A (es) Benzoilpirazoles substituidos con actividad herbicida.
DK1423385T3 (da) Mellemprodukter til fremstilling af neuraminidaseinhibitorkonjugater

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees